Won Sae-Yeon, Kilian Andreas, Dubinski Daniel, Gessler Florian, Dinc Nazife, Lauer Monika, Wolff Robert, Freiman Thomas, Senft Christian, Konczalla Juergen, Forster Marie-Therese, Seifert Volker
Department of Neurosurgery, University Hospital, Goethe-University, Frankfurt am Main, Germany.
Department of Neuroradiology, University Hospital, Goethe-University, Frankfurt am Main, Germany.
Front Oncol. 2020 Nov 20;10:605137. doi: 10.3389/fonc.2020.605137. eCollection 2020.
Surgery of KOOS IV vestibular schwannoma remains challenging regarding the balance of extent of tumor resection (EoR) and functional outcome. Our aim was to evaluate the outcome of surgical resection and define a cut-off value for safe resection with low risk for tumor regrowth of KOOS IV vestibular schwannoma.
All patients presenting at the authors' institution between 2000 and 2019 with surgically treated KOOS IV vestibular schwannoma were included. Outcome measures included EoR, facial/hearing nerve function, surgical complications and progression of residual tumor during the median follow-up period of 28 months.
In 58 patients, mean tumor volume was 17.1 ± 9.2 cm, and mean EoR of 81.6 ± 16.8% could be achieved. Fifty-one patients were available for the follow-up analysis. Growth of residual tumor was observed in 11 patients (21.6%) followed by adjuvant treatment with stereotactic radiosurgery or repeat surgery in 15 patients (29.4%). Overall serviceable hearing preservation was achieved in 38 patients (74.5%) and good facial outcome at discharge was observed in 66.7% of patients, significantly increasing to 82.4% at follow-up. Independent predictors for residual tumor growth was EoR ≤ 87% (OR11.1) with a higher EoR being associated with a very low number of residual tumor progression amounting to 7.1% at follow-up (p=0.008).
Subtotal tumor resection is a good therapeutic concept in patients with KOOS IV vestibular schwannoma resulting in a high rate of good hearing and facial nerve function and a very low rate of subsequent tumor progression. The goal of surgery should be to achieve more than 87% of tumor resection to keep residual tumor progression low.
对于Koos IV级前庭神经鞘瘤手术,在肿瘤切除范围(EoR)和功能结果之间的平衡方面仍然具有挑战性。我们的目的是评估手术切除的结果,并确定Koos IV级前庭神经鞘瘤安全切除且肿瘤复发风险低的临界值。
纳入2000年至2019年在作者所在机构接受手术治疗的所有Koos IV级前庭神经鞘瘤患者。结果指标包括EoR、面/听神经功能、手术并发症以及在中位随访期28个月内残余肿瘤的进展情况。
58例患者的平均肿瘤体积为17.1±9.2 cm,平均EoR可达81.6±16.8%。51例患者可进行随访分析。11例患者(21.6%)观察到残余肿瘤生长,随后15例患者(29.4%)接受了立体定向放射外科辅助治疗或再次手术。38例患者(74.5%)实现了总体有效听力保留,66.7%的患者出院时面部功能良好,随访时显著增至82.4%。残余肿瘤生长的独立预测因素是EoR≤87%(OR11.1),EoR越高,残余肿瘤进展数量非常低,随访时为7.1%(p = 0.008)。
对于Koos IV级前庭神经鞘瘤患者,次全肿瘤切除是一种良好的治疗理念,可实现较高的良好听力和面神经功能率以及极低的后续肿瘤进展率。手术目标应是实现超过87%的肿瘤切除,以降低残余肿瘤进展。